Bristol-Myers Squibb Company Fundamental Analysis (XETRA: BRM.DE)
Bristol-Myers Squibb Company Fundamental Analysis (XETRA: BRM.DE)
Bristol-Myers Squibb Company (XETRA: BRM.DE) shows moderate financial fundamentals with a PE ratio of 14.92, profit margin of 18.86%, and ROE of 46.75%. The company generates $49.2B in annual revenue with weak year-over-year growth of -0.22%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 50.0/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze BRM.DE's fundamental strength across five key dimensions:
Efficiency Score
ExcellentBRM.DE demonstrates superior asset utilization.
Valuation Score
ExcellentBRM.DE trades at attractive valuation levels.
Growth Score
WeakBRM.DE faces weak or negative growth trends.
Financial Health Score
ModerateBRM.DE shows balanced financial health with some risks.
Profitability Score
ExcellentBRM.DE achieves industry-leading margins.
Key Financial Metrics
Is BRM.DE Expensive or Cheap?
P/E Ratio
BRM.DE trades at 14.92 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, BRM.DE's PEG of 0.16 indicates potential undervaluation.
Price to Book
The market values Bristol-Myers Squibb Company at 6.19 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 5.40 times EBITDA. This is generally considered low.
How Well Does BRM.DE Make Money?
Net Profit Margin
For every $100 in sales, Bristol-Myers Squibb Company keeps $18.86 as profit after all expenses.
Operating Margin
Core operations generate 32.88 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $46.75 in profit for every $100 of shareholder equity.
ROA
Bristol-Myers Squibb Company generates $10.57 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Bristol-Myers Squibb Company generates strong operating cash flow of $12.79B, reflecting robust business health.
Free Cash Flow
Bristol-Myers Squibb Company generates strong free cash flow of $11.44B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $5.60 in free cash annually.
FCF Yield
BRM.DE converts 8.27% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
14.92
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.16
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.19
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.82
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
2.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.53
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.47
vs 25 benchmark
ROA
Return on assets percentage
0.11
vs 25 benchmark
ROCE
Return on capital employed
0.23
vs 25 benchmark
How BRM.DE Stacks Against Its Sector Peers
| Metric | BRM.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 14.92 | 32.14 | Better (Cheaper) |
| ROE | 46.75% | 550.00% | Weak |
| Net Margin | 18.86% | 30133.00% | Weak |
| Debt/Equity | 2.02 | 0.56 | Weak (High Leverage) |
| Current Ratio | 1.53 | 5.70 | Neutral |
| ROA | 10.57% | 3.00% | Excellent |
BRM.DE outperforms its industry in 2 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Bristol-Myers Squibb Company's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
25.40%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
186.75%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
11.45%
Industry Style: Defensive, Growth, Innovation
High Growth